Basic Information
| LncRNA/CircRNA Name | LINC-ROR |
| Synonyms | LINC-ROR, ROR, lincRNA-RoR |
| Region | GRCh38_18:57054558-57072119 |
| Ensemble | ENSG00000258609 |
| Refseq | NR_048536 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | OS tissues, established human OS cell lines including Saos-2, U2OS, MG-63 and 143B and normal human osteoblasts, hFOB 1.19, |
| Expression Pattern | up-regulated |
| Function Description | ROR expression level was significantly up regulated in OS tissue samples compared to adjacent normal tissues, and the elevated ROR was closely correlated with advanced tumour node metastasis (TNM) stage and lymph node metastasis and poor overall survival rate. Functional assays showed that ROR knockdown suppressed the OS cell proliferation, colony formation, migration and invasion in vitro, and retarded tumour growth in vivo. In addition, miR 206 was verified to be a target miRNA of ROR using bioinformatics online program and luciferase report assay. miR 206 inhibition partially rescued the inhibitory effects on OS cells induced by ROR knockdown. In conclusion, these results suggested that ROR function as an oncogene in OS by sponging miR 206 and might be a potential therapeutic target for patients with OS. |
| Pubmed ID | 30565392 |
| Year | 2019 |
| Title | The long non-coding RNA-ROR promotes osteosarcoma progression by targeting miR-206 |
External Links
| Links for LINC-ROR | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |